weekly rate of days with services showed no obvious differences before and after the switch but had a clear 8-week pattern (corresponding to the average infusion interval) (Figure) . The total number of services provided was 19,752 (2,019 of these on the switch date). There were significant increases in the rates before vs after switch for 6 of the 16 service categories, although the mean rates were small: telephone consultations (mean rate 1.0 before vs. 1.2 after), patient guidance (0.5 vs. 0.4), intravenous medication (0.0 vs. 0.1), clinical controls (2.1 vs. 2.3) and clinical investigations (0.3 vs. 0.5), whereas the rate of infliximab treatment decreased (3.1 vs 3.0) (all p<0.05, insignificant results not shown).
THU0649 MANDATORY CHOICE OF FIRST BDMARD IN DENMARK -AN OPPORTUNITY TO STUDY REAL-LIFE EFFECTIVENESS? RESULTS FROM THE DANBIO REGISTRY
Objectives: To characterize Danish RA pts initiating first line, first choice treatment with a bDMARD in combination with MTX in the three RADS periods and to explore the degree of compliance to RADS recommendations. Furthermore, to investigate differences in baseline characteristics between those pts who were compliant to RADS guidelines and those who were not. Methods: For each of the three RADS' periods bio-naive pts with RA were identified in DANBIO and compliance to RADS recommendations was assessed. Baseline characteristics of those who started first choice bDMARD treatment according to RADS were compared with those who started another biologic instead. Comorbidities and previous hospitalized infections were identified in the Danish National Patient Registry. Comorbidities from Charlson Comorbidity Index were summarized except category number 7, connective tissue disease. Results: For all three RADS periods, age, gender, functional status and disease activity were typical for pts with RA. Age was median: 57 years, range 18-88 years and disease duration: 3 years, range 0-54 years. 16-22% of pts had ≥1 comorbidity and 7-9% had ≥1 hospitalized infection the previous year. In each of the three RADS periods, 71%, 66% and 60% of pts followed the RADS recommendations, respectively (Table) . The table shows differences between those who started first choice bDMARD treatment according to RADS, and those who did not. Overall, pts who complied to RADS had higher DAS28 and patient VAS global. Characteristics of pts who followed RADS recommendations in the three periods appeared similar.
Conclusions:
In this nationwide study of >600 RA pts, pts' clinical characteristics were more heterogeneous than in clinical trials, reflecting routine care. Overall, compliance to recommendations was good. Thus, the national guidelines in Denmark with mandatory choice of the first biological drug may provide an interesting opportunity to study effectiveness of bDMARDs in routine care. This highlights observational studies as a valuable supplement to RCTs.
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